Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
- PMID:12925554
- DOI: 10.1161/01.HYP.0000086521.95630.5A
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Abstract
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD. In February 2000, the doxazosin treatment arm was discontinued, and findings through December 1999 were reported. This report includes an additional 9232 participant-years and 939 CVD events. At 623 clinical centers, patients (aged >or=55 years) with hypertension and at least 1 other CHD risk factor were randomly assigned to either chlorthalidone or doxazosin. The primary outcome measure was the combined occurrence of fatal CHD or nonfatal myocardial infarction (MI), analyzed by intent to treat; prespecified secondary outcome measures included all-cause mortality, stroke, combined CHD (fatal CHD, nonfatal MI, hospitalized angina, and coronary revascularization), and combined CVD (combined CHD, stroke, angina treated outside the hospital, heart failure, and peripheral arterial disease). Mean follow-up was 3.2 years. There was no difference in primary outcome between the arms (relative risk [RR], 1.02; 95% confidence interval [CI], 0.92 to 1.15). All-cause mortality also did not differ (RR, 1.03; 95% CI, 0.94 to 1.13). However, the doxazosin arm compared with the chlorthalidone arm had a higher risk of stroke (RR, 1.26; 95% CI, 1.10 to 1.46) and combined CVD (RR 1.20; 95% CI, 1.13 to 1.27). These findings confirm the superiority of diuretic-based over alpha-blocker-based antihypertensive treatment for the prevention of CVD.
Similar articles
- Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.[No authors listed][No authors listed]JAMA. 2000 Apr 19;283(15):1967-75.JAMA. 2000.PMID:10789664Clinical Trial.
- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981.JAMA. 2002.PMID:12479763Clinical Trial.
- [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].Scheen AJ, Krzesinski JM.Scheen AJ, et al.Rev Med Liege. 2003 Jan;58(1):47-52.Rev Med Liege. 2003.PMID:12647599Clinical Trial.French.
- [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].Kuwajima I.Kuwajima I.Nihon Rinsho. 2004 Mar;62 Suppl 3:648-53.Nihon Rinsho. 2004.PMID:15171450Review.Japanese.No abstract available.
- Doxazosin and congestive heart failure.Sica DA.Sica DA.Congest Heart Fail. 2002 May-Jun;8(3):178-84. doi: 10.1111/j.1527-5299.2002.00939.x.Congest Heart Fail. 2002.PMID:12045387Review.
Cited by
- Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome.Zhang Y, Zheng W, Liu Y, Wang J, Peng Y, Shang H, Hou N, Hu X, Ding Y, Xiao Y, Wang C, Zeng F, Mao J, Zhang J, Ma D, Sun X, Li C, Xiao RP, Zhang X.Zhang Y, et al.Sci Rep. 2016 Apr 1;6:23957. doi: 10.1038/srep23957.Sci Rep. 2016.PMID:27032687Free PMC article.
- Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Wright JT Jr; ALLHAT Collaborative Research Group.Barzilay JI, et al.Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):153-62. doi: 10.1161/CIRCOUTCOMES.111.962522. Epub 2012 Mar 6.Circ Cardiovasc Qual Outcomes. 2012.PMID:22396585Free PMC article.Clinical Trial.
- Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.Alderman MH, et al.Hypertension. 2012 May;59(5):926-33. doi: 10.1161/HYPERTENSIONAHA.111.180554. Epub 2012 Mar 19.Hypertension. 2012.PMID:22431578Free PMC article.Clinical Trial.
- Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.Park IU, Taylor AL.Park IU, et al.Ann Fam Med. 2007 Sep-Oct;5(5):444-52. doi: 10.1370/afm.708.Ann Fam Med. 2007.PMID:17893387Free PMC article.Review.
- Alpha1-adrenergic blockers: current usage considerations.Sica DA.Sica DA.J Clin Hypertens (Greenwich). 2005 Dec;7(12):757-62. doi: 10.1111/j.1524-6175.2005.05300.x.J Clin Hypertens (Greenwich). 2005.PMID:16330901Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical